TITLE

Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma

AUTHOR(S)
Weiner, P; Weiner, M; Azgad, Y
PUB. DATE
December 1995
SOURCE
Thorax;Dec1995, Vol. 50 Issue 12, p1270
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66103106

 

Related Articles

  • Budesonide/Formoterol: A Review of its Use in Asthma. Goldsmith, David R.; Keating, Gillian M. // Drugs;2004, Vol. 64 Issue 14, p1597 

    Budesonide and formoterol have been combined in a single dry powder device, Symbicort® Turbuhaler® (budesonide/formoterol 160/9–640/18 µg/day), in an effort to simplify asthma management. The efficacy of budesonide/formoterol as maintenance therapy in patients with asthma has...

  • Once-Daily Inhaled Corticosteroids in Mild to Moderate Asthma: Improving Acceptance of Treatment. Campbell, L.M. // Drugs;Dec1999 Supplement 4, Vol. 58 Issue 6, p25 

    Despite the established efficacy of inhaled corticosteroids in improving lung function in asthma, there has not been a corresponding improvement in morbidity and mortality associated with the disease, which, in part, may result from noncompliance with the prescribed regimen. The reasons for this...

  • Budesonide/formoterol maintenance and reliever therapy in moderate-to-severe asthma: Effects on eosinophilic airway inflammation. Takeyama, Kiyoshi; Kondo, Mitsuko; Tagaya, Etsuko; Kirishi, Saori; Ishii, Masanobu; Ochiai, Katsunori; Isono, Kazuo; Tamaoki, Jun // Allergy & Asthma Proceedings;Mar/Apr2014, Vol. 35 Issue 2, p141 

    Although the budesonide and formoterol in a single inhaler for maintenance and reliever therapy has been evaluated in recent studies, the effects on eosinophilic airway inflammation remain uncertain. The purpose of this study was to compare the efficacy, including anti-inflammatory effects, of...

  • Budesonide/Formoterol Pressurized Metered-Dose Inhaler. Lyseng-Williamson, Katherine A.; Simpson, Dene // Drugs;2008, Vol. 68 Issue 13, p1855 

    The corticosteroid budesonide and the long-acting β2-adrenoceptor agonist formoterol have been combined into a single pressurized metered-dose inhaler (pMDI) for use in patients aged ≥12 years with asthma. In well designed 12-week clinical trials in patients with mild to moderate or...

  • Budesonide/Formoterol Pressurized Metered-Dose Inhaler. Lyseng-Williamson, Katherine A; Simpson, Dene // Drugs;2008, Vol. 68 Issue 11, p1855 

    â–´ The corticosteroid budesonide and the long-acting ß2-adrenoceptor agonist formoterol have been combined into a single pressurized metered-dose inhaler (pMDI) for use in patients aged ≥12 years with asthma.â–´ In well designed 12-week clinical trials...

  • Efficacy and Safety of Budesonide and Formoterol in One Pressurised Metered-Dose Inhaler in Adults and Adolescents with Moderate to Severe Asthma. Noonan, Michael; Rosenwasser, Lanny J.; Martin, Paula; O'Brien, Christopher D.; O'Dowd, Liza // Drugs;2006, Vol. 66 Issue 17, p2235 

    Background: Inhaled corticosteroids (ICSs) are the preferred maintenance therapy for adults and children with mild, moderate and severe persistent asthma, with the addition of a long-acting β2-adrenoceptor agonist to ICS therapy recommended for patients with moderate or severe persistent...

  • Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma. Korenblat, Phillip E.; Rosenwasser, Lanny J. // Allergy & Asthma Proceedings;May/Jun2010, Vol. 31 Issue 3, p190 

    The combination of budesonide and formoterol administered in one hydrofluoroalkane pressurized metered-dose inhaler (pMDI) is approved in the United States in two dosage strengths (budesonide/formoterol pMDI 80/4.5 μg × 2 inhalations [160/9 μg] or 160/4.5 μg × 2 inhalations...

  • The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children. Berger, William E.; Leflein, Jeffrey G.; Geller, David E.; Parasuraman, Bhash; Miller, Christopher J.; O'Brien, Christopher D.; O'Dowd, Liza // Allergy & Asthma Proceedings;Jan/Feb2010, Vol. 31 Issue 1, p26 

    Few studies have evaluated inhaled corticosteroid (ICS)/long-acting beta2-adrenergic agonist combination therapy in asthmatic children. This study was designed to evaluate the safety (primary) and clinical benefits (secondary) of budesonide/formoterol pressurized metered-dose inhaler (pMDI)...

  • Formoterol/budesonide pressurized metered-dose inhaler: a guide to its use in chronic obstructive pulmonary disease. Lyseng-Williamson, Katherine // Drugs & Therapy Perspectives;Aug2014, Vol. 30 Issue 8, p269 

    The use of a single pressurized metered-dose inhaler (pMDI) containing both formoterol (a long-acting β-selective adrenoreceptor agonist) and budesonide (an inhaled corticosteroid) is an effective, convenient and well- tolerated option for the treatment of adults with symptoms of moderate to...

  • Is budesonide or nedocromil superior in the long-term management of mild to moderate asthma in children? Stella, Meri Feaver; Newton, Warren // Journal of Family Practice;Jan2001, Vol. 50 Issue 1, p70 

    The article discusses research being done on the long-term effects of budesonide or nedocromil in children with asthma, with reference to a study by the Childhood Asthma Management Program Research Group, which was published in the 2000 issue of the "New England Journal of Medicine." The...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics